Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otsuka Holdings CoSTU:OS1 +3.31%87 EV-to-EBITDA is 8.27 as of Jul. 31, 2026, which is 12% below its 10-year median of 9.43. GuruFocus rates STU:OS1 with a GF Score™ of 87/100 and a GF Value™ of €45.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 747 Drug Manufacturers companies, Otsuka Holdings Co ranks better than 66.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Otsuka Holdings Co's enterprise value is €30,091 Mil.
Otsuka Holdings Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €3,640 Mil. Therefore, Otsuka Holdings Co's EV-to-EBITDA for today is 8.27.
The historical rank and industry rank for Otsuka Holdings Co's EV-to-EBITDA or its related term are showing as below:
STU:OS1'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.99 Med: 9.43 Max: 18.72
Current: 9.05
During the past 13 years, the highest EV-to-EBITDA of Otsuka Holdings Co was 18.72. The lowest was 5.99. And the median was 9.43.
STU:OS1's EV-to-EBITDA is ranked better than 66.53% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs STU:OS1: 9.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Otsuka Holdings Co (STU:OS1) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Otsuka Holdings Co's PE Ratio (TTM) for today is calculated as:
Otsuka Holdings Co's share price for today is €62.50.
Otsuka Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Otsuka Holdings Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OS1 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Otsuka Holdings Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otsuka Holdings Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Otsuka Holdings Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Otsuka Holdings Co's EV-to-EBITDA falls into.
Otsuka Holdings Co's current Enterprise Value is €30,091 Mil.
Otsuka Holdings Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,640 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otsuka Holdings Co (STU:OS1) has a EV-to-EBITDA of 8.27 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Otsuka Holdings Co. This is 12% below median its historical median of 9.43. Over the past decade, Otsuka Holdings Co's EV-to-EBITDA has ranged from 5.99 to 18.72. According to the industry distribution chart, Otsuka Holdings Co ranks #250 out of 747 companies in the Drug Manufacturers industry, placing it in the top 33.5%.
Is Otsuka Holdings Co's EV-to-EBITDA too high?
Otsuka Holdings Co's current EV-to-EBITDA of 8.27 is 12% below median its 10-year median of 9.43. Over the past 10 years, this metric has ranged from a low of 5.99 to a high of 18.72. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. Otsuka Holdings Co's value of 8.27 is 35.8% below this industry median. Based on the distribution chart, Otsuka Holdings Co ranks #250 out of 747 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Otsuka Holdings Co has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Otsuka Holdings Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Otsuka Holdings Co ranks #250 out of 747 companies for EV-to-EBITDA. This puts Otsuka Holdings Co in the upper half of its industry. The industry median EV-to-EBITDA is 12.88. Otsuka Holdings Co's value of 8.27 is 35.8% below this benchmark. Historically, Otsuka Holdings Co's own EV-to-EBITDA has ranged from 5.99 to 18.72 over the past decade. While the company's 10-year median is 9.43 vs. the industry median of 12.88, Otsuka Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otsuka Holdings Co's current EV-to-EBITDA of 8.27 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Otsuka Holdings Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otsuka Holdings Co's current EV-to-EBITDA is 8.27, which is 12% below median its own 10-year median of 9.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otsuka Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Otsuka Holdings Co (STU:OS1) is currently considered Significantly Overvalued. The stock's GF Value™ is €45.14, compared to a current price of €62.50 — trading 38.5% above its estimated fair value. The current EV-to-EBITDA is 8.27, which is 12% below median its 10-year median of 9.43 and 35.8% below the Drug Manufacturers industry median of 12.88. Otsuka Holdings Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Otsuka Holdings Co (STU:OS1), the current EV-to-EBITDA is 8.27 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Otsuka Holdings Co (STU:OS1) Overvalued in 2026?
Based on GuruFocus' analysis, Otsuka Holdings Co stock appears to be overvalued.
The current stock price of €62.50 is trading 38.5% above its estimated GF Value™ of €45.14.
GuruFocus considers Otsuka Holdings Co to be Significantly Overvalued.
Key valuation signals for STU:OS1:
EV-to-EBITDA: 8.27 (12% below median its 10-year median of 9.43)
GF Value™: €45.14 vs. price of €62.50 (38.5% above fair value)
Industry Position: 35.8% below the Drug Manufacturers median (#250 of 747)
No single metric tells the full story. See the STU:OS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
87GF Score
Get the complete analysis for STU:OS1
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OS1 has been successfully added to your 
